No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Household & Personal Products
Established on July 1, 2000, NeoPharm Co., Ltd. is a Daejeon, South Korea-based company that develops, produces, and markets a diverse range of cosmetic, medical, and health products. Its offerings notably include advanced skincare formulations, both emulsified and functional, designed to address issues such as sensitive and dry skin, as well as to provide treatment for atopic dermatitis, psoriasis, and the adverse effects associated with steroid use.
www.neopharm.co.krNo one on the platform currently holds 092730.KQ.
No tracked institution reports a position in 092730.KQ as of their last filing.
No one on the platform has traded 092730.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.6% | 13.0% | 18.0% | — | — | — |
| Rev. Growth % | 11.1% | 10.1% | ||||
| Profit Margin % | 21.1% | 20.9% | 21.3% | |||
| Free Cash Flow Margin % | 20.6% | 16.1% | 17.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $168.0B | +26.9% | $2013.00 | $2013.00–$2013.00 | — | 1 |
| 2027 | $205.0B | +22.0% | $2597.00 | $2597.00–$2597.00 | — | 1 |
| 2028 | $244.0B | +19.0% | $3063.00 | $3063.00–$3063.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $9430.00 |
| +0.43% |
| $323.4B |
| — |
| 044820.KSCosmax BTI, Inc. | $23950.00 | +4.59% | $228.8B | — |
| 078520.KSAble C&C Co., Ltd. | $9980.00 | -1.48% | $250.5B | — |
Source: Financial Modeling Prep · peers by sector/industry